Natco Pharma Launches First Generic Hep C Med in India
Source: Business Standard
Jan 02, 2017
Hyderabad-based Natco Pharma has launched the first generic version of Gilead's Sofosbuvir in Nepal.
Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, under the brand name Epclusa.
Natco will market Sofosbuvir under the name Velpanat as a single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Read the Business Standard coverage
Show Comments
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Comments
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments